[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unruptured-cerebral-aneurysm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unruptured-cerebral-aneurysm":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,39,52,83,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100590863","neurovascular-navigation-with-remotely-controlled-deflectable-guidewire-study-i-neuronav-study-i-100590863",false,"NCT06972953","NEUROvascular NAVigation With Remotely Controlled Deflectable Guidewire, Study I (NeuroNAV Study I)","Inclusion Criteria:\n\n* \\>18 years of age\n* Informed consent signed by the patient\n* Confirmed cerebral unruptured aneurysm treatable via transcatheter approach\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Known disorder of vascular fragility with propensity to vascular injury (e.g., Ehlers-Danlos syndrome)\n* Known prior vascular stenosis or dissection or injury to vessels intended to be catheterized during study procedures\n* Acute phase myocardial infarction or uncontrolled cardiac arrhythmia\n* Uncontrolled serum electrolyte imbalance\n* Bleeding disorder which limits the use of antiplatelet and\u002For anticoagulant therapy\n* Known contraindication to intravascular contrast material that cannot be adequately controlled with pre-medication\n* Known hypersensitivity to Nickel\n* Subjects currently enrolled in another investigational device or drug study that clinically interferes with the current study endpoints","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"NA","The aim of the study is to confirm the safe and successful use of the SmartGUIDE guidewire, when used in neuro interventions. The performance of the SmartGUIDE guidewire in terms of safe and successful navigation within the neurovasculature will be compared to standard of care guidewire on the market.",[25],"Unruptured Cerebral Aneurysm","RECRUITING","2026-01-18",{"date":29,"type":30},"2026-01-21","ACTUAL",{"date":32,"type":30},"2025-06-16",{"date":34,"type":19},"2026-12",{"name":36,"class":37},"Artiria Medical","INDUSTRY",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":20,"phases":45,"briefSummary":23,"conditions":46,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":47,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":51,"locationsCount":38},"100590864","neurovascular-navigation-with-remotely-controlled-deflectable-guidewire-study-ii-neuronav-study-ii-100590864","NCT06972966","NEUROvascular NAVigation With Remotely Controlled Deflectable Guidewire, Study II (NeuroNAV Study II)",{"count":18,"type":19},[22],[25],{"date":29,"type":30},{"date":49,"type":30},"2025-06-18",{"date":34,"type":19},{"name":36,"class":37},{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":20,"phases":62,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100374449","comprehensive-aneurysm-management-trial-100374449","NCT04155606","Comprehensive Aneurysm Management Trial","The Comprehensive Aneurysm Management Trial","CAM","Inclusion Criteria:\n\n* Patients with at least one documented, intracranial subarachnoid aneurysm (cavernous aneurysms are excluded)\n\nExclusion Criteria:\n\n* Patients with any intracranial hemorrhage, including SAH, within the previous 30 days\n* Patients with AVM-associated aneurysms\n* Patients unable to give informed consent",{"count":61,"type":19},2000,[22],"The uncertainty regarding the management of Unruptured Intracranial Aneurysms (UIAs) has not progressed in the last 30 years. The fundamental ethical basis for this study is that physicians should only offer a risky preventive treatment when it has been shown to be beneficial. Before that, such treatment should be offered as an RCT. The CAM trial offers a comprehensive framework, so that all patients confronted with the clinical dilemma can be offered participation.\n\nThe principal questions to be addressed are :\n\n1. do patients with UIAs, considered for curative treatments, have a better long-term clinical outcome with active treatment or conservative management?\n2. when patients are considered ineligible for conservative management, and surgical and endovascular management are both judged reasonable, do patients with UIAs have a better long-term clinical outcome with surgical or endovascular management? The primary hypothesis for patients allocated to at least 2 options, one of which is conservative management is: the 10 year combined neurological morbidity and mortality (mRS\\>2) will be reduced from 24% to 16% (beta 80%; alpha 0.048; sample size 961 patients (836 plus 15% losses to FU and cross-overs) with active treatment.\n\nThis study is designed as a pragmatic, comprehensive way to address the unruptured aneurysm clinical dilemma, combining large simple RCTs whenever patients are judged eligible for more than one management option, or otherwise a registry of each option. All patients with one or more UIAs will be eligible for participation in either a registry or one of the trials. Patients will be followed for 10 years according to a standard of car follow-up schedule.\n\nThe primary outcome is survival without neurological dependency (mRS\\\u003C3) at 10 years.\n\nThe secondary outcomes are:\n\n1. the incidence of SAH during follow-up and related morbidity and mortality;\n2. the morbidity and mortality related to endovascular or surgical treatment of the UIA at one year;\n3. overall mortality at 1, 5 and 10 years;\n4. overall morbidity (mRS\\>2) at 1, 5 and 10 years;\n5. length of hospitalization;\n6. discharge to location other than home",[65,66,25],"Saccular Aneurysm","Intracranial Aneurysm",[68,69,70,71],"Unruptured Intracranial Aneurysm","Endovascular treatment","Surgical treatment","Conservative management","2025-07-23",{"date":74,"type":30},"2025-07-28",{"date":76,"type":30},"2020-01-15",{"date":78,"type":19},"2036-01",{"name":80,"class":81},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",6,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":91,"targetDuration":93,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":38},"100574987","ai-models-for-cerebral-aneurysms-segmentation-detection-and-stability-prediction-100574987","NCT06766422","AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction","Artificial Intelligence Applications for Cerebral Aneurysms Segmentation, Detection and Stability Prediction: a Stepwise, Multicenter Study","AI-CARE","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Preliminary diagnosis or symptoms indicating the presence or potential presence of a cerebral aneurysm;\n3. Undergoing a non-contrast head MRA or contrast-enhanced head\u002Fneck CTA;\n4. The patient or their legal representative is able and willing to sign an informed consent form.\n\nExclusion Criteria:\n\n1. Other intracranial vascular diseases: moyamoya disease, arteriovenous malformations, arteriovenous fistulas, arterial occlusions, and arterial dissections;\n2. History of intracranial arterial interventions: stent placement, partial aneurysm coil treatment, etc.;\n3. Severe allergy to contrast agents or absolute contraindications to iodine-based contrast agents;\n4. Renal insufficiency with elevated serum creatinine (greater than twice the upper normal limit);\n5. MRI contraindications: pacemakers, claustrophobia, etc.;\n6. Diseases or conditions that affect the quality of CTA\u002FMRA images;\n7. Inability to complete the study due to psychiatric disorders, cognitive, or emotional disturbances.\n\nNote: The CTA sub-study does not include exclusion criterion 5; the MRA sub-study does not include exclusion criteria 3 and 4.",{"count":92,"type":19},10000,"1 Year","OBSERVATIONAL","Aneurysmal subarachnoid hemorrhage (SAH) is one of the critical diseases that severely threaten human health, with a clinical mortality rate reaching as high as 30%. Early diagnosis and intervention before rupture are considered key to improving the prognosis of aneurysmal SAH. With the widespread clinical application of non-invasive cerebrovascular imaging techniques, such as CTA and MRA, the detection rate of unruptured intracranial aneurysms (UIAs) has significantly increased. However, addressing the growing demand for clinical cerebrovascular imaging diagnostics raises the challenge of improving diagnostic accuracy while alleviating the workload of diagnostic physicians. Furthermore, considering that not all detected UIAs will rupture, it is crucial to accurately identify high-risk aneurysms prone to rupture to avoid unnecessary overtreatment, which could lead to significant socioeconomic burdens and iatrogenic harm to patients.To meet this clinical need, researchers have developed an artificial intelligence (AI) algorithm to create software capable of automatically identifying intracranial aneurysms based on non-invasive vascular imaging data, enabling accurate diagnosis of aneurysms. To evaluate the clinical utility of this AI algorithm, a prospective, multicenter, registry study was proposed. Through long-term standardized and uniform non-invasive imaging follow-up, individualized imaging analysis profiles will be established. By correlating these profiles with aneurysm outcome events (growth or rupture), imaging features capable of accurately predicting aneurysm growth and rupture will be identified and analyzed. This approach is expected to enhance the accuracy of UIA diagnosis and enable risk stratification for unruptured intracranial aneurysms through the utilization of relevant data.",[25,97,98,99],"Artificial Intelligence (AI)","Subarachnoid Hemorrhage, Aneurysmal","Magnetic Resonance Angiography",[101,102,99,103],"Artificial Intelligence","Cerebral Aneurysms","Subarachnoid Hemorrhage","2025-05-31",{"date":106,"type":30},"2025-06-03",{"date":108,"type":30},"2025-01-10",{"date":110,"type":19},"2027-06-30",{"name":112,"class":81},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":20,"phases":122,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},"100357638","the-rise-trial-a-randomized-trial-on-intra-saccular-endobridge-devices-100357638","NCT03936647","The RISE Trial: A Randomized Trial on Intra-Saccular Endobridge Devices","RISE","Inclusion Criteria:\n\n* patient with an intracranial aneurysm in whom WEB is considered an appropriate therapeutic option by the participating clinician\n* aneurysm of maximum diameter of 4-11 mm\n* may include (but are not restricted to) saccular bifurcation aneurysms of the middle cerebral artery, basilar bifurcation, carotid terminus, or anterior communicating artery aneurysms\n* Recurring, persistent aneurysm after previous treatment can be included so long as the treating physician judges the aneurysm morphology to be appropriate.\n* Ruptured aneurysms with WFNS ≤ 3\n\nExclusion Criteria:\n\n* Absolute contraindication to surgery, endovascular treatment or anesthesia\n* Patients unable to give informed consent\n* diameter of the aneurysm ≤ 4 mm but ≥ 11 mm\n* Ruptured aneurysms with WFNS 4 or 5",{"count":121,"type":19},250,[22],"Intracranial bifurcation aneurysms are commonly repaired with surgical and with endovascular techniques. Wide-necked bifurcation aneurysms (WNBA) are a difficult subset of aneurysms to successfully repair endovascularly, and a number of treatment adjuncts have been designed. One particularly promising innovation is the WEB (Woven EndoBridge), which permits placement of an intra-saccular flow diverting mesh across the aneurysm neck, but which does not require anti-platelet agent therapy. Currently, which treatment option leads to the best outcome for patients with WNBA remains unknown. There is a need to offer treatment with the WEB within the context of a randomized care trial, to patients currently presenting with aneurysms thought to be suitable for the WEB.",[66,125,25,126,127],"Brain Aneurysm","Ruptured Cerebral Aneurysm","Cerebral Aneurysm",[129,130,131,132,133,134,135],"intracranial aneurysm","cerebral aneurysm","brain aneurysm","unruptured cerebral aneurysm","ruptured cerebral aneurysm","WEB embolization device","embolization","2024-08-13",{"date":138,"type":30},"2024-08-15",{"date":140,"type":30},"2019-07-18",{"date":142,"type":19},"2026-01",{"name":80,"class":81},4]